BIOMAT Database Logo BIOMAT Database Logo

Initial clinical experience with clinafloxacin in the treatment of serious infections. 1995

K J Tack, and N M McGuire, and I A Eiseman
Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan, USA.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases

Related Publications

K J Tack, and N M McGuire, and I A Eiseman
Clinical experience with cefotaxime in the treatment of serious bone and joint infections.
January 1982, Reviews of infectious diseases,
K J Tack, and N M McGuire, and I A Eiseman
Initial antibiotic treatment of serious bacterial infections.
January 2019, Vnitrni lekarstvi,
K J Tack, and N M McGuire, and I A Eiseman
Clinical experience with cefamandole for treatment of serious bone and joint infections.
May 1978, The Journal of infectious diseases,
K J Tack, and N M McGuire, and I A Eiseman
Open-label, multicentre, emergency-use study of clinafloxacin (CI-960) in the treatment of patients with serious life-threatening infections.
March 2002, International journal of antimicrobial agents,
K J Tack, and N M McGuire, and I A Eiseman
Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients.
February 2011, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
K J Tack, and N M McGuire, and I A Eiseman
Cefoperazone monotherapy for serious infections in hospitalized patients--an initial Indian experience.
June 1995, The Journal of the Association of Physicians of India,
K J Tack, and N M McGuire, and I A Eiseman
Clinical experience with lower doses of cefotaxime in hospitalized patients with serious infections.
July 1989, Journal of chemotherapy (Florence, Italy),
K J Tack, and N M McGuire, and I A Eiseman
Initial therapy of serious bacterial infections.
April 1971, Delaware medical journal,
K J Tack, and N M McGuire, and I A Eiseman
An open study of Timentin for the initial treatment of serious infections.
May 1986, The Journal of antimicrobial chemotherapy,
K J Tack, and N M McGuire, and I A Eiseman
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
April 2019, International journal of antimicrobial agents,
Copied contents to your clipboard!